Resources Repository
-
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Preferences/Values | Costing Methods | North America | Policy/Regulation | Benefit-Cost Analysis | Chronic Disease/Risk | Mental Health | Economics/Finance | Government/Law | Health/Medicine -
DataWeb Portal 2024Healthcare Cost and Utilization Project (HCUP)
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in …
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in the United States, including information on in-patient care, ambulatory care, and emergency department visits. HCUP enables researchers, insurers, policymakers and others to study health care delivery and patient outcomes over time, and at the national, regional, State, and community levels. The Agency for Healthcare Research and Quality (AHRQ) provides a range of data resources in the form of online, searchable…
Costing Methods | North America | Policy/Regulation | Maternal/Reproductive Health | Health Outcomes | Evidence Synthesis | Test Performance | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Costing Methods | North America | Policy/Regulation | Maternal/Reproductive Health | Health Outcomes | Test Performance | Decision Analysis | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology -
BookPublication 2016Cost-Effectiveness in Health and Medicine, 2nd Edition
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The …
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The Second Panel on Cost-Effectiveness in Health and Medicine included experts drawn from academia, healthcare administration, and government. The book offers advice for conducting analyses to improve the allocation of health resources, and is intended for economists, policy analysts, hospital executives, and students across health, business, and humanities disciplines. New components of this edition, include an in-depth review of the past 20…
Preferences/Values | Costing Methods | North America | Policy/Regulation | Priority Setting/Ethics | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Economics/Finance | Health/Medicine | Global | Europe -
ReviewPublication 2016Strengthening Cost-Effectiveness Analysis for Public Health Policy
Many important opportunities to improve health lie outside the health sector and involve improving the …
Many important opportunities to improve health lie outside the health sector and involve improving the conditions in which we live and work: safe design and maintenance of roads, bridges, train tracks, and airports; control of environmental pollutants; occupational safety; healthy buildings; a safe and healthy food supply; safe manufacture of consumer products; a healthy social environment; and others. Faced with the overwhelming array of possibilities, U.S. decision makers need help identifying those that can contribute the…
Preferences/Values | Costing Methods | North America | Policy/Regulation | Priority Setting/Ethics | Cost-Effectiveness Analysis | Social Determinants | Environmental Health | Health Systems | Climate/Environment | Economics/Finance | Food/Agriculture | Health/Medicine -
BookPublication 2016Cost-Effectiveness Analysis in Health: A Practical Approach, 3rd Edition
Cost-Effectiveness Analysis in Health provides an introduction to the tools, methods, and procedures used to perform cost-effectiveness research. …
Cost-Effectiveness Analysis in Health provides an introduction to the tools, methods, and procedures used to perform cost-effectiveness research. This third edition contains new discussion on meta-analysis and advanced modeling techniques, a worked example using visual modeling software TreeAge Pro, and updated recommendations from the U.S. Public Health Service's Panel on Cost-Effectiveness in Health and Medicine. The book provides process-specific instruction in a concise, structured format to highlight common methods and techniques for: 1) Developing a thoroughly fleshed-out research project; 2) Working…
Preferences/Values | Costing Methods | North America | Policy/Regulation | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Economics/Finance | Health/Medicine -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Preferences/Values | Costing Methods | North America | Policy/Regulation | Priority Setting/Ethics | Health Outcomes | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine -
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
State-Transition | North America | Policy/Regulation | Mathematical Models | Benefit-Cost Analysis | Infectious Diseases | Business/Industry | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
State-Transition | North America | Policy/Regulation | Value of Information | Benefit-Cost Analysis | Infectious Diseases | Economics/Finance | Europe